| Literature DB >> 29652899 |
Anika Thielmann1, Biljana Gerasimovska-Kitanovska2, Tuomas H Koskela3, Vildan Mevsim4, Birgitta Weltermann5.
Abstract
INTRODUCTION: Common colds are the most frequently encountered disease worldwide and the most frequent reason for self-care. According to the cross-sectional European Common Colds study (COCO), patients use as many as 12 items on average for self-care. Little is known about the influence of discomfort and knowledge on self-care for common colds. MAINEntities:
Mesh:
Year: 2018 PMID: 29652899 PMCID: PMC5898731 DOI: 10.1371/journal.pone.0195564
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characteristics of the COCO study sites and participants (n = 2,204).
| n | % | ||
|---|---|---|---|
| Gender, female | 1,360 | 62.5 | |
| Mean age (SD) | 46.5 (16.4) | ||
| Insurance status, public | 2,052 | 96.4 | |
| Non-smoker | 1,683 | 77.8 | |
| Patients with ≥1 self-reported chronic condition: | 871 | 39.5 | |
| Hypertension | 488 | 56.0 | |
| Chronic pain/arthritis/osteoarthritis | 215 | 24.7 | |
| Heart disease | 192 | 22.0 | |
| Diabetes | 170 | 19.5 | |
| Asthma/chronic bronchitis | 151 | 17.3 | |
| Depression | 117 | 13.4 | |
| Chronic kidney disease | 44 | 5.1 | |
| Number of tablets used daily (mean, SD) | 2.0 | 2.76 | |
| Patients with ≥1 tablets daily (n = 1,204): | |||
| ASA | 256 | 21.3 | |
| Oral contraceptive | 134 | 11.1 | |
| Anticoagulants | 56 | 4.7 | |
| Austria | 86 | 3.9 | |
| Finland | 77 | 3.5 | |
| France, 3 sites | 265 | 12.0 | |
| Germany, 3 sites | 292 | 13.2 | |
| Israel | 104 | 4.7 | |
| Italy, 2 sites | 148 | 6.7 | |
| Macedonia | 269 | 12.2 | |
| Poland, 2 sites | 195 | 8.8 | |
| Slovenia | 89 | 4.0 | |
| Spain | 64 | 2.9 | |
| Sweden | 77 | 3.5 | |
| Turkey, 5 sites | 538 | 24.4 | |
*ASA = acetylsalicylic acid
°mixed (urban/rural)
+urban
Self-care behavior stratified by four patient groups based on the presence and/or absence of knowledge about the self-limited disease course and subjective discomfort during the last common cold (n = 2,204).
| Group 1 ☺ | Group 2 | Group 3 | Group 4 ☹ | p-value | |||||
|---|---|---|---|---|---|---|---|---|---|
| (+) knowledge (-) discomfort | (-) knowledge (-) discomfort | (+) knowledge (+) discomfort | (-) knowledge (+) discomfort | ||||||
| 510 | 23.1 | 138 | 6.3 | 894 | 40.6 | 662 | 30.0 | ||
| Age, mean | 48.4±17.29 | 48.7±16.41 | 46.1±16.27 | 45.2±15.75 | <0.01 | ||||
| Gender: female, % | 54.9 | 56.0 | 63.7 | 68.1 | <0.001 | ||||
| Years of school (including higher education), mean | 13.3±4.16 | 10.7±4.82 | 13.3±4.39 | 12.3±4.52 | <0.001 | ||||
| 8.8±5.50 | 11.1±6.30 | 11.9±6.45 | 13.3±7.39 | <0.001 | |||||
| n | % | n | % | n | % | n | % | ||
| Foodstuffs | 465 | 131 | 860 | 643 | <0.001 | ||||
| Intestinal absorption | 358 | 97 | 775 | 543 | <0.001 | ||||
| Extras at home | 48 | 15 | 107 | 114 | <0.001 | ||||
| Intranasal use | 235 | 58 | 521 | 350 | <0.001 | ||||
| Inhalation | 155 | 57 | 321 | 261 | <0.01 | ||||
| Local oral effects | 138 | 48 | 339 | 247 | <0.001 | ||||
| Topical use in throat | 124 | 50 | 289 | 282 | <0.001 | ||||
| External use | 334 | 103 | 763 | 576 | <0.001 | ||||
| Foodstuffs | 4.2±3.25 | 5.7±3.64 | 5.1±3.54 | 6.1±3.99 | <0.001 | ||||
| Intestinal absorption | 1.4±1.30 | 1.5±1.47 | 2.1±1.59 | 2.1±1.74 | <0.001 | ||||
| Extras at home | 1.5±1.55 | 1.9±1.71 | 2.3±1.80 | 2.5±1.85 | <0.001 | ||||
| Intranasal use | 0.5±0.66 | 0.5±0.65 | 0.7±0.74 | 0.6±0.69 | <0.001 | ||||
| Inhalation | 0.5±0.78 | 0.6±0.78 | 0.6±0.93 | 0.6±1.03 | 0.011 | ||||
| Local oral effects | 0.4±0.69 | 0.5±0.75 | 0.6±0.88 | 0.5±0.81 | <0.001 | ||||
| Topical use in throat | 0.3±0.52 | 0.4±0.57 | 0.4±0.56 | 0.5±0.65 | <0.001 | ||||
| External use | 0.1±0.36 | 0.1±0.34 | 0.1±0.41 | 0.2±0.48 | <0.001 | ||||
| Non-pharmaceutical products | 8.1±5.36 | 10.5±6.09 | 10.9±6.29 | 12.4±7.06 | <0.001 | ||||
| Pharmaceutical products | 0.7±0.78 | 0.6±0.77 | 1.0±0.87 | 0.8±0.88 | <0.001 | ||||
| 1:6.7 | 1:10.0 | 1:9.1 | 1:10.1 | <0.001 | |||||
| Without evidence base | 7.9±5.3 | 10.4±6.1 | 10.7±6.3 | 12.2±7.0 | <0.001 | ||||
| With evidence base | 0.9±0.9 | 0.7±0.9 | 1.3±1.0 | 1.0±1.0 | <0.001 | ||||
| 1:6.1 | 1:9.6 | 1:7.8 | 1:9.6 | <0.001 | |||||
#Kruskal-Wallis test
*Significant after correcting for multiple testing using the Benjamini & Hochberg procedure
Fig 1Logistic regression analysis for high self-care use (n = 2,084).